Enhancement of oral bioavailability of phenytoin by esterification, and in vitro hydrolytic characteristics of prodrugs

[1]  A. Yamamoto,et al.  Effects of various absorption enhancers on the intestinal absorption of water soluble drugs by in vitro Ussing chamber method: correlation with an in situ absorption experiment. , 1997, Biological & pharmaceutical bulletin.

[2]  G. Scriba,et al.  Bioavailability and anticonvulsant activity of 2-cyanoguanidinophenytoin, a structural analogue of phenytoin. , 1996, Journal of pharmaceutical sciences.

[3]  G. Scriba,et al.  Bioavailability of Phenytoin Following Oral Administration of Phenytoin‐lipid Conjugates to Rats , 1995, The Journal of pharmacy and pharmacology.

[4]  G. Scriba,et al.  Bioavailability and anticonvulsant activity of a monoglyceride-derived prodrug of phenytoin after oral administration to rats. , 1995, Journal of pharmaceutical sciences.

[5]  G. Scriba,et al.  Anticonvulsant Activity of Phenytoin‐lipid Conjugates, a New Class of Phenytoin Prodrugs , 1995, The Journal of pharmacy and pharmacology.

[6]  M. Iwaki,et al.  Physicochemical and hydrolytic characteristics of phenytoin derivatives. , 1994, Biological & pharmaceutical bulletin.

[7]  M. Iwaki,et al.  Pharmacokinetic analysis of phenytoin and its derivatives in plasma and brain in rats. , 1993, Biological & pharmaceutical bulletin.

[8]  T. Vree,et al.  Pharmacokinetic analysis of ester prodrugs of valproic acid. , 1992, Journal of pharmaceutical sciences.

[9]  N. Bodor,et al.  Improved anticonvulsant activity of phenytoin by a redox brain delivery system I: Synthesis and some properties of the dihydropyridine derivatives. , 1989, Journal of pharmaceutical sciences.

[10]  T. Nagai,et al.  Dissolution and bioavailability of phenytoin in phenytoin-polyvinylpyrrolidone-sodium deoxycholate coprecipitate. , 1986, Chemical & pharmaceutical bulletin.

[11]  M. Bialer,et al.  Pharmacokinetic evaluation of novel sustained-release dosage forms of valproic acid in humans. , 1985, Biopharmaceutics & drug disposition.

[12]  V. Stella,et al.  Prodrugs , 1985, Drugs.

[13]  S. Varia,et al.  Phenytoin prodrugs III: water-soluble prodrugs for oral and/or parenteral use. , 1984, Journal of pharmaceutical sciences.

[14]  S. Varia,et al.  Phenytoin prodrugs VI: In vivo evaluation of a phosphate ester prodrug of phenytoin after parenteral administration to rats. , 1984, Journal of pharmaceutical sciences.

[15]  P. Bansal,et al.  N-hydroxymethyl derivatives of nitrogen heterocycles as possible prodrugs I: N-hydroxymethylation of uracils. , 1981, Journal of pharmaceutical sciences.

[16]  T. Higuchi,et al.  N-hydroxymethyl derivatives of nitrogen heterocycles as possible prodrugs II: possible prodrugs of allopurinol, glutethimide, and phenobarbital. , 1981, Journal of pharmaceutical sciences.

[17]  T. Arita,et al.  Dissolution behaviors and gastrointestinal absorption of phenytoin in phenytoin-polyvinylpyrrolidone coprecipitate. , 1978, Chemical & pharmaceutical bulletin.

[18]  M. Gibaldi,et al.  Plasma protein binding and metabolic clearance of phenytoin in the rat. , 1977, The Journal of pharmacology and experimental therapeutics.

[19]  R. Baldessarini,et al.  Hydrolysis of diester prodrugs of apomorphine. , 1977, Biochemical pharmacology.

[20]  W. L. Weller,et al.  Study of dose-dependent metabolism of 5,5-diphenyl-hydantoin in the rat using new methodology for isolation and quantitation of metabolites in vivo and in vitro. , 1971, The Journal of pharmacology and experimental therapeutics.

[21]  K. Nakamura,et al.  Pharmacological studies of a new anti-inflammatory drug, 1-phenylsulfonyl-5,5-diphenylhydantoin (PC-796) in experimental animals. I. Anti-inflammatory, analgesic and anti-pyretic activity. , 1970, Arzneimittel-Forschung.

[22]  K. Arnold,et al.  The rate of decline of diphenylhydantoin in human plasma , 1970, Clinical pharmacology and therapeutics.

[23]  K. Nakatsuji,et al.  The anticonvulsant activity of 3-ethoxycarbonyl-5,5-diphenylhydantoin (P-6127) in animals. , 1965, Archives internationales de pharmacodynamie et de therapie.

[24]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[25]  Gerhard K. E. Scriba.  Synthesis and in vitro Evaluation of 4‐(2‐Glyceryl)butyric Acid: A Glyceride Mimic for Drug Delivery via Drug‐Lipid Conjugates. Synthese und in vitro Charakterisierung der 4‐(2‐Glyceryl)buttersäure: Ein Glyceridanalogon für “Drug Delivery” mittels Arzneistoff‐Lipid Konjugaten , 1994 .

[26]  T Nakagawa,et al.  A pharmacokinetic analysis program (multi) for microcomputer. , 1981, Journal of pharmacobio-dynamics.

[27]  R. Upton.  Simple and reliable method for serial sampling of blood from rats. , 1975, Journal of pharmaceutical sciences.

[28]  G. Levy,et al.  ABSORPTION AND DISSOLUTION STUDIES ON DIPHENYLHYDANTOIN CAPSULES , 1970 .